RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    2.
    发明申请
    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS 审中-公开
    表达结构性HCV抗原的重组MVA

    公开(公告)号:US20110293656A1

    公开(公告)日:2011-12-01

    申请号:US13110471

    申请日:2011-05-18

    摘要: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

    摘要翻译: 本发明涉及能够表达结构HCV抗原,所述结构抗原的功能部分或所述结构抗原表位的重组MVA。 本发明进一步涉及一种药物组合物,特别是疫苗形式,并含有本发明的重组体MVA,其含有本发明的重组MVA的真核细胞以及重组MVA的各种用途,例如用于产生重组结构 蛋白质,用于制备适于治疗和预防由此引起的HCV感染和疾病的药物制剂。 本发明还涉及用于产生由所述重组MVA编码的重组MVA和重组结构HCV多肽以及所述重组MVA的DNA或RNA的方法。

    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS
    3.
    发明申请
    RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS 审中-公开
    表达结构性HCV抗原的重组MVA

    公开(公告)号:US20090238843A1

    公开(公告)日:2009-09-24

    申请号:US12476696

    申请日:2009-06-02

    IPC分类号: A61K39/12 C12N5/10 C07H21/04

    摘要: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.

    摘要翻译: 本发明涉及能够表达结构HCV抗原,所述结构抗原的功能部分或所述结构抗原表位的重组MVA。 本发明进一步涉及一种药物组合物,特别是疫苗形式,并含有本发明的重组体MVA,其含有本发明的重组MVA的真核细胞以及重组MVA的各种用途,例如用于产生重组结构 蛋白质,用于制备适于治疗和预防由此引起的HCV感染和疾病的药物制剂。 本发明还涉及用于产生由所述重组MVA编码的重组MVA和重组结构HCV多肽以及所述重组MVA的DNA或RNA的方法。